

STANFORD UNIVERSITY SCHOOL OF MEDICINE
STANFORD MEDICAL CENTER
PALO ALTO, CALIFORNIA 94304

DEPARTMENT OF PREVENTIVE MEDICINE

June 3, 1969

Area Code 415
321-1200

AIRMAIL SPECIAL DELIVERY

Dr. Christian Klint, Chairman
Dept. of Epidemiology & Biostatistics
Institute of International Medicine
University of Maryland
660 West Redwood Street
Baltimore, Maryland 21201

Dear Chris:

I am sorry that I will not be at the Williamsburg meeting, but there seems to be such a strong consensus among the consultants, advisers, coordinating center staff, and executive committee, that I have no doubt that our common view will be well presented and defended.

This note will serve the purpose of confirming my agreement with the position arrived at on Monday, May twenty-sixth, in the conference involving you, Curt, Genell, and Jerry Cornfield, with Max and Bob as observers. I feel very strongly that the evidence against Tolbutamide dictates termination of the medication in this study. I feel that the patients should be changed over to placebo, and followed to termination of the study. Furthermore, I feel that evidence argues, though rather more weakly, for a similar action in the case of Phenformin. However, I do feel that the continuation of Phenformin medication in the study has some merit and I would agree to and defend this view as the consensus of our group and that of the Executive Committee.

I regard this problem as extremely important, and I hope that I have been of some help to you in thinking about it.

Please let me know what the final decision is, and call on me if you feel that I can be of any help in the future.

Sincerely yours,

BW

Byron Wm. Brown, Jr., Chairman
Division of Biostatistics

BWB:C

cc also to Williamsburg Motor House
Williamsburg, Virginia 23185